NRX PHARMACEUTICALS, INC. — Cash Flow Charts
33 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+5.2% +$191K
$-3M
Free Cash Flow↑+5.2% +$191K
$-3M
Investing Cash Flow
$0
Financing Cash Flow↑+141.4% +$3M
$5M
Capex
$0
Acquisitions
$3M
Stock Buybacks↓-96.6% -$9M
$299K
Stock-Based Comp↑+88.4% +$38K
$81K
D&A↑+4100.0% +$41K
$42K
SBC Allocated Expense↓-25.0% -$11K
$33K
SBC Unrecognized Cost↓-81.3% -$1M
$300K